CIAN
REGN icon

Capstone Investment Advisors (Netherlands)’s Regeneron Pharmaceuticals REGN Stock Holding History

Capstone Investment Advisors (Netherlands)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-435
Closed -$160K – 162
2016
Q4 		$160K Buy
+435
New +$165K 0.27% 150

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Capstone Investment Advisors (Netherlands)'s REGN Position: Q1 2017 in Review

Capstone Investment Advisors (Netherlands) sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 435 shares — an estimated $160K sold.

Capstone Investment Advisors (Netherlands) first reported a position in REGN in Q4 2016 and held it in 1 quarter. The position peaked at $160K in Q4 2016. 578 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

  • Capstone Investment Advisors (Netherlands) reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Capstone Investment Advisors (Netherlands) sold 435 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $160K.
  • Capstone Investment Advisors (Netherlands) first reported a position in Regeneron Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Capstone Investment Advisors (Netherlands)'s Regeneron Pharmaceuticals position peaked at $160K in Q4 2016.
  • 578 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Capstone Investment Advisors (Netherlands)'s 13F filing for Q1 2017, filed 15 May 2017.